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Abstract
Present day 24-h Holter monitors have been shown to miss many arrhythmias that may occur
infrequently or under specific circumstances. The advancement in electronic and adhesive
technologies have enabled the development of first generation wearable long-term 14-day patch
ECG monitors that attach directly to the skin and require no electrodes and wires to operate.
This new technology is unobtrusive to the patients and offers them unprecedented mobility. It
enables very long-term monitoring of critical patients while they are carrying out daily activi-
ties. The monitors are waterproof, offer good adhesion to the skin and can operate as either
recorders or wireless streaming devices. (Cardiol J 2012; 19, 2: 210–214)
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Introduction
This review paper describes the representative
wearable electrocardiogram (ECG) devices in both
recording and wirelessly transmitting categories.
A brief overview of their potential applications to
the arrhythmia monitoring, ST-T segment changes
and management is also provided.
The limitations of the traditional Holter record-
ers are well known [1] in the literature. Rapidly pro-
gressing medical device technology may soon over-
come these limitations however and future Holters
may have the following characteristics:
— very long recording periods — weeks or even
months to accurately capture the arrhythmic
episodes, ST changes and long-term dynamic
ECG patterns;
— there will be no wires or electrodes on the pa-
tient chest;
— very small size will make “wearing” these de-
vices finally possible;
— wireless communication capability for instan-
taneous reporting of cardiac events during the
monitoring period;
— user attachable, water proof patch form;
— extensive signal processing capability for ac-
curate arrhythmia detection and ECG wave-
form analysis;
— multiple sensors such as accelerometer, tem-
perature, etc., will be included along the ECG
application specific integrated circuit (ASIC);
— wireless recharging and/or energy harvesting
capability.
The major shortcomings of standard 24 h
Holters include poor detection rates of transient
arrhythmic events.
Senatore et al. [2] studied incidence of asympto-
matic recurrences of atrial fibrillation (AF) by daily
transtelephonic (TT) ECG monitoring, as compared
with standard ECG and 24-h Holter recording, in pa-
tients who underwent radiofrequency catheter abla-
tion (RCA) of AF. Long-term TT ECG was better
than standard ECG and 24-h Holter recordings in eva-
luating AF relapses after RCA, thus decreasing the
short-term success of ablation from 86% to 72%. The
authors concluded that the absence of symptoms should
not be interpreted as absence of AF, as 50% of patients
were asymptomatic during at least one AF episode.
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Piorkowski et al. [3] compared TT ECG every
2 days and serial 7-day Holter as 2 methods of fol-
low-up after AF catheter ablation to determine the
ablation success. The success rate in terms of free-
dom from AF was 70% on a symptom-only-based
follow-up; using serial 7-day Holter it decreased to
50% and on TT monitoring to 45%, respectively.
Transtelephonic ECG and serial 7-day Holter were
equally effective in determining long-term success
and to detect asymptomatic patients
Dagres et al. [4] investigated the influence of
Holter duration on the detection of recurrences af-
ter ablation for AF and reported that a 24-h Holter
would have detected 59%, a 48-h Holter 67% and
a 72-h Holter 80% of patients with recurrences,
whereas a 4-day recording would have detected
91% of the recurrences that were detected with the
complete 7-day recording.
Hanke et al. [5] studied the accuracy of cardiac
rhythm assessment after surgical ablation therapy
as compared to implantable cardiac rhythm moni-
toring (IMD) device (Reveal XT 9525). Rhythm
control readings were derived simultaneously from
24HM Holter and IMD at 3-month intervals with
a total recording of 2021 h for 24HM and 220 766 h
for IMD. Sinus rhythm was documented in 53 read-
ings of 24HM, but in only 34 of these instances by
the IMD in the time period before 24HM readings
(64%, p < 0.0001), reflecting a 24HR Holter sensi-
tivity of 0.60 and a negative predictive value of
0.64 for detecting AF recurrence. The authors con-
cluded that for ”real-life” cardiac rhythm documen-
tation, continuous heart rhythm surveillance in-
stead of any conventional 24HM follow-up strate-
gy is necessary. This is particularly important for
further judgment of ablation techniques, devices as
well as anticoagulation and antiarrhythmic therapy.
Jabaudon et al. [6] reported that 7-day ambula-
tory ECG monitoring using an event-loop record-
ing device would detect otherwise occult episodes
AF and atrial flutter after acute stroke or transient
ischemic attack.
Recent technological advances resulted in de-
velopment of single use, wearable ECG monitoring
devices capable of continuously recording ECG sig-
nals for 7, 14 day or even longer periods. Such de-
vices comprise a pressure sensitive adhesive patch
with an embedded electronic circuit attached to the
patient’s chest. The idea behind the wearable Patch
ECG Monitors (PEM) is to record ECG signals
without visible electrodes and lead wires.
Typical PEM features a very low power, ASIC,
wireless network interface and an extremely small
footprint. Wearable Patch ECG Monitors may also
include motion, temperature and impedance sen-
sors [7, 8]. Together, these sensors provide more
patient information than standard 3-lead Holter re-
corders as shown in Figure 1.
Numerous academic and commercial institu-
tions are presently engaged in development and
Figure 1. The wearable Patch ECG Monitors runs on a cloud computing platform. The ECG data is transmitted locally
from the free living subject wearing a sensor patch to a gateway Hand-Held device via a micro Bluetooth wireless
link. The Hand-Held device has enough computing power to perform automatic arrhythmia detection. The alarms
together with ECG data are transferred via a fast wireless Internet link to the processing servers where the data is
further analyzed and stored. The patient and the doctor access the ECG records on the server via specialized client
applications. Adapted from [9].
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commercialization of PEMs, which fall into two
broad categories: (1) recording devices only and
(2) recording and transmitting devices [10, 11]. In
this paper we’ll discuss most representative devic-
es currently commercially available from these two
broad categories.
Recording only PEM — single lead
The most representative device in this cate-
gory is Zio Patch from iRhythm Technologies of San
Francisco, California [12]. As per manufacturer’s
data, it is a waterproof single use, long-term cardi-
ac rhythm monitor that provides continuous moni-
toring for up-to-14 days (Fig. 2).
By providing a longer time period of continu-
ous recording, the Zio Patch improves the likelihood
of capturing arrhythmias and provides for an equal
or higher diagnostic yield versus other devices on
the market.
The Zio Patch is indicated for use on patients
who may be asymptomatic or who may suffer from
transient symptoms such as palpitations, dizziness,
light-headedness, pre-syncope and syncope, short-
ness of breath, anxiety and fatigue. The Zio Patch
constantly records the heart’s electrical activity and
was designed to be worn comfortably during nor-
mal daily activities, including showering and sleep.
The ease of use and inconspicuousness of the Zio
Patch helps increase the likelihood that a patient
will wear the device for the entire prescribed mon-
itoring period. If the patient has a symptom, they
can mark the time of the symptom by pushing
a button on the Zio Patch to allow their physician
to correlate their symptom with the rhythm of their
heart. At the end of the patient’s monitoring peri-
od, the patient sends the Zio Patch to the iRhythm’s
processing center for analyzis. Upon receipt of the
Zio Patch, iRhythm will provide the physician with
a comprehensive easy-to-read report.
The Zio ECG Utilization Service (ZEUS) sys-
tem is a comprehensive system that processes and
analyzes received ECG data captured by long-du-
ration, single-lead, continuous recording diagnos-
tic devices, such as the Zio Patch. The ZEUS sys-
tem uses beat-by-beat QRS detection and a sophis-
ticated rhythm analysis algorithm to detect up to
ten categories of rhythms. ZEUS runs on a cloud-
computing platform and can be used to analyze up
to 14 days of ECG data more rapidly and accurately
than traditional systems. The data processed by the
ZEUS algorithm is reviewed by a Certified Cardio-
graphic Technician to help ensure high accuracy and
quality. iRhythm has received Food and Drug
Administration (FDA) 510(k) clearance for both the
Zio Patch, and the companion ZEUS algorithm and
software system.
Recording and wirelessly
transmitting PEM — single lead
NUVANT Mobile Cardiac Telemetry (MCT)
System by Corventis, San Jose, California, revolves
around the chest worn PiiX electrocardiograph,
a high precision single lead ECG, which sends read-
ings to a mobile phone based device for further
transmission of the data to a hosted application for
clinician’s access. The NUVANT MCT System has
been designed with a specific focus on ambulatory
arrhythmia monitoring, the NUVANT MCT System
leverages the low profile form factor, advanced al-
gorithms and multi-sensor capabilities of the PiiX
wearable platform to enable continuous monitoring
for a broad set of arrhythmias, including AF, as well
as patient falls that may be associated with arrhyth-
mias. Patients can also trigger the collection of an
ECG, on-demand, upon experiencing symptoms,
further aiding in the correlation of symptoms with
the ECG (Fig. 3).
Figure 3. Piix multi-sensor, waterproof patch placed on
the patient’s chest.
Figure 2. Single lead Zio Patch long term wearable ECG
recording device comprises two sensors placed 82 mm
from each other.
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All ECGs are transmitted to the Corventis
Monitoring Center via the wireless-enabled zLink,
for review and response by trained cardiographic
technicians as shown in Figure 4. Physicians re-
ceive prompt notification of urgent events as well
as actionable information in the form of Episode
Reports, Daily Reports and End of Use Reports via
fax, email and/or the secure www.corventis.com
website. Using this information, a physician can
diagnose symptomatic and asymptomatic cardiac
arrhythmias and proactively manage patients re-
motely from anywhere across the globe. Corventis
has received FDA 510(k) clearance for the NUVANT
MCT System.
Other single lead transmitting PEMs include
Curvus [13] WIN Human Recorder [14], and Tau-
maz [15].
Recording and wirelessly
transmitting PEM — three lead
Another noteworthy 3-lead device has been de-
veloped by IMEC and the Holst Centre [16]. This in-
novative PEM integrates an ultra-low power ECG chip
and a Bluetooth Low Energy (BLE) radio (Fig. 5).
The patch fuses power-efficient electronics and
standardized communication. The ECG patch
records up to 3 lead ECG signals, tissue-contact
impedance and includes a 3D-accelerometer for
physical activity monitoring. The data are processed
and analyzed locally, and relevant events and infor-
mation are transmitted through BLE wireless link.
The PEM is capable of monitoring, processing and
communication on a minimal energy budget. When
computing and transmitting the heart rate, the en-
tire system consumes 280 µA at 2.1 V, running con-
tinuously for 1 month on a 200 mAh Li-Po battery.
When transmitting accelerometer data (at 32 Hz)
on top of the heart rate, the power consumption
remains below 1 mA in continuous operation, giv-
ing about 1 week of autonomy. The PEM uses
a communication gateway to mobile devices such as
smart phones and tablets. At the heart of the patch
is an ECG SoC, a mixed signal ASIC. It is custom
designed integrated circuit to provide ECG moni-
toring and signal processing at extremely low pow-
er consumption. In addition to monitoring 1- to 3-
-lead ECG, the PEM also monitors the contact im-
pedance, providing real-time information on the
sensor contact quality. The impedance data can then
be used to evaluate the quality of the ECG measure-
ment and to aid in filtering motion artifacts.
The ECG SoC has been designed to run al-
gorithms for motion artifact reduction (based on
Figure 4. Workflow of the NUVANT Mobile Cardiac Te-
lemetry (MCT) System. The ECG data is recorded by
the PiiX patch and sent wirelessly to zLink Mobile Trans-
mitter, which forwards it to the monitoring center. Phy-
sicians access the data in the monitoring center via
a client application.
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automatically
collecting and
transmitting data
Wireless
communication
zLink Mobile
Transmitter Corventis Monitoring Center
Physician access
Figure 5. The flexible circuit board of the 3-lead PEM
developed by IMEC.
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adaptive filtering or principal component analyzis)
and beat-to-beat heart rate computation (based on
discrete or continuous wavelet transforms). It has
additional computation power to run application-
specific algorithms such as epileptic seizure detec-
tion or arrhythmia monitoring. The built-in 12-bit
ADC is capable of adaptive sampling — sampling
the QRS segments at high frequency, and the rest
of the ECG at a lower frequency thus achieving
a data compression ratio of up to 5. IMEC PEM is
still undergoing further development and is not
available commercially.
Other 3-lead PEMs include V-Patch [17] and
Novosense [18].
Conclusions
Patch ECG Monitors offer patient friendly,
non-obtrusive, electrode and lead wire free record-
ing environment. PEMs’ ability to record ECG data
for very long-time periods will allow clinicians to
better diagnose arrhythmic events. Present day de-
vices are limited to maximum of 3-leads and these
still require a periodic replacement of the electrodes
[8]. Of particular interest would be studies analyz-
ing the sensitivity and specificity of the recordings.
Another potential limitation of these devices is their
problematic measurement artifact immunity and
their ability to measure discernible QRS and
P waveforms in the presence of noise. As the devi-
ces get more popular in the market place, we can
expect the improvements in their functionality and
more accurate data acquisition. On balance, we can
reasonably expect the Patch ECG Monitor techno-
logy to evolve and result in wearable 12-lead de-
vices in a near future.
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